Niagen Bioscience, Inc. — Director's Dealing 2023

Jun 1, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ChromaDex Corp. (CDXC)
CIK: 0001386570
Period of Report: 2023-05-31

Reporting Person: Fried Robert N (Director, Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-05-31	Common Stock	P	7000	$1.42	Acquired	95001	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	972314	Direct
Common Stock	250000	Indirect
Common Stock	250000	Indirect
Common Stock	12746	Indirect

Footnotes

F1: 6,745 shares of Common Stock held by Jeremy Fried and 6,001 shares of Common Stock held by Benjamin Fried, who are both sons of Robert Fried.